>>I interpret this to mean that the FXR target of ENTA’s preclinical drug has been “validated” by ICPT’s OCA; hence, if ENTA’s drug is somehow better than OCA, it could end up being a significant asset.
That would be a great reason to buy ENTA, IMO.
It is astonishing what foolish things one can temporarily believe if one thinks too long alone ... where it is often impossible to bring one's ideas to a conclusive test either formal or experimental. J.M. Keynes